Log in or Sign up for Free to view tailored content for your specialty!
Menopause News
Link between fatty liver disease, hot flash severity ‘hard to tease apart’
Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.
LGBTQ+ women veterans report fewer midlife sexual dysfunction symptoms
Heterosexual midlife women veterans reported more sexual dysfunction and impact from vaginal symptoms and were less likely to be sexually active compared with sexual minority counterparts, according to findings published in Menopause.
Mediterranean diet named best overall for 8th straight year
For the 8th year in a row, the Mediterranean diet has been named the best overall diet by the editors of U.S. News and World Report, the company announced.
Log in or Sign up for Free to view tailored content for your specialty!
Long-term follow-up in anogenital lichen sclerosus needed to prevent morbidities
Anogenital lichen sclerosus can lead to permanent anatomical changes and sexual discomfort in women, highlighting a need for long-term follow-up and high treatment adherence, the latter of which is lacking, according to a study.
FDA adds boxed warning to hot flash drug Veozah due to liver injury risk
The FDA added a boxed warning to highlight known risk for rare but serious liver injury associated with the use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot flashes, according to an agency press release.
Early menopause tied to higher risk for incident heart failure
Women with menopause onset before age 45 years were more likely to develop incident heart failure regardless of serum adipokine levels, according to study findings published in Menopause.
Q&A: Multimorbidity in postmenopausal women ‘a new health challenge’
Women are living, on average, 5 years longer than men with an improved overall quality of life, but with an increased lifespan comes greater risk for multimorbidity, particularly after the menopause transition.
CV risks vary based on menopausal hormone therapy combinations, administration methods
Cardiovascular disease risks vary depending on the type of menopausal hormone therapy combinations and administration methods used, according to a nationwide trial published in The BMJ.
No cognitive impact 10 years after short-term, early menopausal hormone therapy: KEEPS
Short-term exposure to hormone therapy started within 3 years of menopause was not associated with long-term cognitive impairment or benefit, according to data from the KEEPS Continuation study.
VIDEO: Mount Sinai conference spotlights latest treatments, wellness for midlife women
In this Healio video exclusive, Joanne Stone, MD, MS, and Susan S. Khalil, MD, discussed highlights from the second annual Mount Sinai Women’s Health Forum, a 1-day conference dedicated to the latest updates in care for midlife women.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read